Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva/Eisai rasagiline deal

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Eisai will co-promote Teva's MAO-B inhibitor rasagiline in North America for Parkinson's disease under a deal that also calls for global co-development for Alzheimer's disease. Teva recently announced successful completion of its Phase III Parkinson's program, with an FDA filing set for second half 2003 (1Pharmaceutical Approvals Monthly May 1, p. 14)...

Related Content

Japanese Pharma Sea Change: U.S. Development Takes Focus Over Licensing
Teva rasagiline submission
Teva Rasagiline Filing Set For Second Half 2003; Firm Touts Metabolic Profile





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts